Department of Pediatrics, Hanil General Hospital , Seoul, Republic of Korea.
Department of Pediatrics, Incheon St. Mary's Hospital, The Catholic University of Korea , Incheon, Republic of Korea.
Hum Vaccin Immunother. 2020 Dec 1;16(12):3090-3097. doi: 10.1080/21645515.2020.1748978. Epub 2020 Apr 24.
This study was conducted to assess the nasopharyngeal (NP) carriage and acute otitis media (AOM) occurrence in Korean children who received pneumococcal conjugate vaccines (PCVs). The longitudinal study was conducted through four consecutive visits. At each visit, NP aspirates were obtained and subjects were asked to visit if AOM occurred. A total of 305 subjects were enrolled and received PCV13 (n = 182) or PCV10 (n = 123). In the PCV13 group, the NP carriage of at each visit was 2.7%, 14.8%, 18.7%, and 15.9%, respectively. Non-typeable (NTHi) was 3.3%, 2.7%, 2.7%, and 5.5%, and that of was 1.1%, 9.3%, 4.9%, and 0.5%. In the PCV10 group, the NP carriage of at each visit was 3.3%, 7.3%, 6.5%, and 4.1%, respectively. That of NTHi was 2.4%, 4.1%, 1.6%, and 0.8%, and that of was 4.1%, 0.8%, 0.8%, and 0.0%. AOM occurrence in the PCV13 group observed after the primary dose and before booster dose was 20.9%, occurrence after booster dose was 11.0%, and the incidence of two or more AOM was 11.0%. In the PCV10 group, AOM occurrence was 9.8%, 7.3%, respectively, and the incidence of two or more AOM was 2.4%. The predominant isolated were non-vaccine type (10A, 15A, and 15B). In this study, AOM occurrence was lower in the PCV10 group than in the PCV13 group. This seems to be related to ecological changes that lead to differences in NP carriage, especially and NTHi.
本研究旨在评估接种肺炎球菌结合疫苗（PCV）的韩国儿童的鼻咽（NP）携带和急性中耳炎（AOM）发生情况。该纵向研究通过连续四次就诊进行。每次就诊时，均采集 NP 抽吸物，并在发生 AOM 时要求受试者就诊。共纳入 305 名受试者，分别接受 PCV13（n=182）或 PCV10（n=123）接种。在 PCV13 组中，每次就诊的 NP 携带率分别为 2.7%、14.8%、18.7%和 15.9%。非定型 （NTHi）分别为 3.3%、2.7%、2.7%和 5.5%，而 为 1.1%、9.3%、4.9%和 0.5%。在 PCV10 组中，每次就诊的 NP 携带率分别为 3.3%、7.3%、6.5%和 4.1%。NTHi 分别为 2.4%、4.1%、1.6%和 0.8%，而 分别为 4.1%、0.8%、0.8%和 0.0%。PCV13 组在基础剂量后和加强剂量前观察到的 AOM 发生率为 20.9%，加强剂量后的发生率为 11.0%，两次或多次 AOM 的发生率为 11.0%。在 PCV10 组中，AOM 的发生率分别为 9.8%和 7.3%，两次或多次 AOM 的发生率为 2.4%。分离的主要 为非疫苗型（10A、15A 和 15B）。在本研究中，PCV10 组的 AOM 发生率低于 PCV13 组。这似乎与导致 NP 携带差异的生态变化有关，尤其是 和 NTHi。
